CoChat

Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice

Open access
Almeida, Camila Bononi, Scheiermann, Christoph, Jang, Jung-Eun, Prophete, Colette, Costa, Fernando Ferreira, Conran, Nicola, Frenette, Paul S. · 2012 · Blood
Cited by 116

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Inhibition of leukocyte adhesion to the vascular endothelium represents a novel and important approach for decreasing sickle cell disease (SCD) vaso-occlusion. Using a humanized SCD–mouse-model of tumor necrosis factor-α–induced acute vaso-occlusion, we herein present data demonstrating that short-term administration of either hydroxyurea or the phosphodiesterase 9 (PDE9) inhibitor, BAY73-6691, significantly altered leukocyte recruitment to the microvasculature. Notably, the administration of both agents led to marked improvements in leukocyte rolling and adhesion and decreased heterotypic red blood cell-leukocyte interactions, coupled with prolonged animal survival. Mechanistically, these rheologic benefits were associated with decreased endothelial adhesion molecule expression, as well as diminished leukocyte Mac-1-integrin activation and cyclic guanosine monophosphate (cGMP)–signaling, leading to reduced leukocyte recruitment. Our findings indicate that hydroxyurea has immediate beneficial effects on the microvasculature in acute sickle-cell crises that are independent of the drug's fetal hemoglobin-elevating properties and probably involve the formation of intravascular nitric oxide. In addition, inhibition of PDE9, an enzyme highly expressed in hematopoietic cells, amplified the cGMP-elevating effects of hydroxyurea and may represent a promising and more tissue-specific adjuvant therapy for this disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2012-02-409524

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 43

  1. Stuart, 2004, Sickle-cell disease., Lancet, 364, 1343, 10.1016/S0140-6736(04)17192-4 · DOI · Paper page
  2. Hebbel, 1980, Erythrocyte adherence to endothelium in sickle-cell anemia: a possible determinant of disease severity., N Engl J Med, 302, 992, 10.1056/NEJM198005013021803 · DOI · Paper page
  3. Frenette, 2007, Sickle cell disease: old discoveries, new concepts, and future promise., J Clin Invest, 117, 850, 10.1172/JCI30920 · DOI · Paper page
  4. Turhan, 2002, Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm., Proc Nat Acad Sci U S A, 99, 3047, 10.1073/pnas.052522799 · DOI · Paper page
  5. Belcher, 2003, Transgenic sickle mice have vascular inflammation., Blood, 101, 3953, 10.1182/blood-2002-10-3313 · DOI · Paper page
  6. Aslan, 2007, Redox-dependent impairment of vascular function in sickle cell disease., Free Radic Biol Med, 43, 1469, 10.1016/j.freeradbiomed.2007.08.014 · DOI
  7. Turhan, 2004, Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes., Blood, 103, 2397, 10.1182/blood-2003-07-2209 · DOI · Paper page
  8. Hidalgo, 2009, Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury., Nat Med, 15, 384, 10.1038/nm.1939 · DOI · Paper page
  9. Chaar, 2010, Aggregation of mononuclear and red blood cells through α4β1-Lu/BCAM interaction in sickle cell disease., Haematologica, 95, 1841, 10.3324/haematol.2010.026294 · DOI
  10. Head, 2010, Beneficial effects of nitric oxide breathing in adult patients with sickle cell crisis., Am J Hematol, 85, 800, 10.1002/ajh.21832 · DOI
  11. Montero-Huerta, 2006, Inhaled nitric oxide for treatment of sickle cell stroke., Anesthesiology, 105, 619, 10.1097/00000542-200609000-00028 · DOI
  12. Kaul, 2008, Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress., Am J Physiol Heart Circ Physiol, 295, H39, 10.1152/ajpheart.00162.2008 · DOI · Paper page
  13. de Franceschi, 2003, Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation., Blood, 102, 1087, 10.1182/blood-2002-07-2135 · DOI · Paper page
  14. Martinez-Ruiz, 2001, Inhaled nitric oxide improves survival rates during hypoxia in a sickle cell (SAD) mouse model., Anesthesiology, 94, 1113, 10.1097/00000542-200106000-00028 · DOI
  15. Rosse, 2000, New views of sickle cell disease pathophysiology and treatment., Hematology Am Soc Hematol Educ Program, 2000, 2, 10.1182/asheducation.V2000.1.2.20000002 · DOI
  16. McGann, 2011, Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?, Curr Opin Hematol, 18, 158, 10.1097/MOH.0b013e32834521dd · DOI · Paper page
  17. King, 2004, Nitric oxide production from hydroxyurea., Free Radical Biol Med, 37, 737, 10.1016/j.freeradbiomed.2004.02.073 · DOI
  18. Cokic, 2003, Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase., J Clin Invest, 111, 231, 10.1172/JCI200316672 · DOI · Paper page
  19. Bender, 2006, Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use., Pharmacol Rev, 58, 488, 10.1124/pr.58.3.5 · DOI · Paper page
  20. Ikuta, 2001, Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway., Proc Nat Acad Sci U S A, 98, 1847, 10.1073/pnas.98.4.1847 · DOI
  21. Canalli, 2008, Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation., Haematologica, 93, 605, 10.3324/haematol.12119 · DOI · Paper page
  22. Almeida, 2008, High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils., Br J Haematol, 142, 836, 10.1111/j.1365-2141.2008.07264.x · DOI
  23. Miguel, 2011, Inhibition of phosphodiesterase 9A (PDE9A) reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anemia individuals., Inflamm Res, 60, 633, 10.1007/s00011-011-0315-8 · DOI
  24. Jang, 2011, CXCL1 and its receptor, CXCR2, mediate murine sickle cell vaso-occlusion during hemolytic transfusion reactions., J Clin Invest, 121, 1397, 10.1172/JCI45336 · DOI · Paper page
  25. Belcher, 2005, Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice., Am J Physiol Heart Circ Physiol, 288, H2715, 10.1152/ajpheart.00986.2004 · DOI · Paper page
  26. Kaul, 2000, Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice., J Clin Invest, 106, 411, 10.1172/JCI9225 · DOI · Paper page
  27. Lanaro, 2009, Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy., J Leukoc Biol, 85, 235, 10.1189/jlb.0708445 · DOI · Paper page
  28. Lebensburger, 2010, Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model., Haematologica, 95, 1599, 10.3324/haematol.2010.023325 · DOI
  29. Cokic, 2006, Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells., Blood, 108, 184, 10.1182/blood-2005-11-4454 · DOI
  30. Kato, 2009, Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions., Am J Hematol, 84, 618, 10.1002/ajh.21475 · DOI · Paper page
  31. Cokic, 2008, Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells., Blood, 111, 1117, 10.1182/blood-2007-05-088732 · DOI · Paper page
  32. Xu, 2011, Hydroxyurea enhances SMN2 gene expression through nitric oxide release., Neurogenetics, 12, 19, 10.1007/s10048-010-0268-z · DOI
  33. Rodriguez, 1998, A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea., Blood, 91, 1533, 10.1182/blood.V91.5.1533 · DOI
  34. Reyes-Irisarri, 2007, Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains., Eur J Neurosci, 25, 3332, 10.1111/j.1460-9568.2007.05589.x · DOI
  35. Wunder, 2005, Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line., Mol Pharmacol, 68, 1775, 10.1124/mol.105.017608 · DOI
  36. Lebensburger, 2012, Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin., Blood, 119, 1915, 10.1182/blood-2011-08-374447 · DOI
  37. Zarbock, 2008, PSGL-1 engagement by E-selectin signals through Src kinase Fgr and ITAM adapters DAP12 and FcR gamma to induce slow leukocyte rolling., J Exp Med, 205, 2339, 10.1084/jem.20072660 · DOI · Paper page
  38. Luo, 2007, Structural basis of integrin regulation and signaling., Annu Rev Immunol, 25, 619, 10.1146/annurev.immunol.25.022106.141618 · DOI · Paper page
  39. Tang, 2006, Down-regulation of integrin alpha M beta 2 ligand-binding function by the urokinase-type plasminogen activator receptor., Biochem Biophys Res Commun, 348, 1184, 10.1016/j.bbrc.2006.07.179 · DOI
  40. Machado, 2011, Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity., Blood, 118, 855, 10.1182/blood-2010-09-306167 · DOI · Paper page
  41. Hutson, 2011, The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents., Neuropharmacology, 61, 665, 10.1016/j.neuropharm.2011.05.009 · DOI
  42. Kroker, 2012, Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP., Neuropharmacology, 62, 1964, 10.1016/j.neuropharm.2011.12.021 · DOI
  43. Gladwin, 2002, Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease., Br J Haematol, 116, 436, 10.1046/j.1365-2141.2002.03274.x · DOI · Paper page

Cited by

See all 116

Metadata

Authors
Almeida, C. B., Scheiermann, C., Jang, J.-E., Prophete, C., Costa, F. F., Conran, N., & Frenette, P. S.
Venue
Blood
Published
2012-10-04
Volume
120
Issue
14
Pages
2879-2888
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2027955104
Cited by
116
References
7
FWCI
3.33
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. https://app.cochat.ai/papers/10.1182/blood-2012-02-409524
The paper
Almeida, C. B., Scheiermann, C., Jang, J.-E., Prophete, C., Costa, F. F., Conran, N., & Frenette, P. S. (2012). Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. Blood. https://doi.org/10.1182/blood-2012-02-409524

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.